[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medtronic Inc (MDT)

Medtronic Inc (MDT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,844,880
  • Shares Outstanding, K 1,283,885
  • Annual Sales, $ 33,537 M
  • Annual Income, $ 4,662 M
  • EBIT $ 7,957 M
  • EBITDA $ 10,818 M
  • 60-Month Beta 0.62
  • Price/Sales 2.77
  • Price/Cash Flow 9.91
  • Price/Book 2.00

Options Overview Details

View History
  • Implied Volatility 31.41% (-0.19%)
  • Historical Volatility 24.31%
  • IV Percentile 99%
  • IV Rank 94.29%
  • IV High 32.46% on 05/11/26
  • IV Low 14.14% on 12/09/25
  • Expected Move (DTE 1) 0.95 (1.24%)
  • Put/Call Vol Ratio 3.27
  • Today's Volume 11,854
  • Volume Avg (30-Day) 10,983
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 184,710
  • Open Int (30-Day) 143,086
  • Expected Range 76.02 to 77.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate $1.58
  • Number of Estimates 10
  • High Estimate $1.69
  • Low Estimate $1.53
  • Prior Year $1.62
  • Growth Rate Est. (year over year) -2.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.40 +3.45%
on 05/11/26
87.90 -12.44%
on 04/15/26
-11.15 (-12.65%)
since 04/14/26
3-Month
74.40 +3.45%
on 05/11/26
98.98 -22.24%
on 02/23/26
-22.52 (-22.64%)
since 02/13/26
52-Week
74.40 +3.45%
on 05/11/26
106.33 -27.61%
on 11/26/25
-7.28 (-8.64%)
since 05/14/25

Most Recent Stories

More News
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking...

LGND : 218.98 (-1.01%)
MDT : 76.97 (+1.00%)
OBIO : 4.11 (+1.23%)
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026  Orchestra BioMed and Medtronic plc. (NYSE: MDT, “Medtronic”), the...

MDT : 76.97 (+1.00%)
OBIO : 4.11 (+1.23%)
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest...

LGND : 218.98 (-1.01%)
MDT : 76.97 (+1.00%)
OBIO : 4.11 (+1.23%)
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval...

MDT : 76.97 (+1.00%)
OBIO : 4.11 (+1.23%)
Medtronic Stock Outlook: Is Wall Street Bullish or Bearish?

Although Medtronic has lagged behind the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

XLV : 146.63 (-0.05%)
$SPX : 7,501.24 (+0.77%)
MDT : 76.97 (+1.00%)
3 Reasons Analysts Love DexCom

Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.

MDT : 76.97 (+1.00%)
DXCM : 57.82 (-1.28%)
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension...

MDT : 76.97 (+1.00%)
OBIO : 4.11 (+1.23%)
Medtronic announces CE Mark for Stealth AXiS™ surgical system

Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe

MDT : 76.97 (+1.00%)
Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

GALWAY, Ireland and CHICAGO , April 25, 2026 /PRNewswire/ -- Medtronic plc, (NYSE: MDT), a global leader in healthcare technology, today announced continued momentum for the Affera™ family of technologies...

MDT : 76.97 (+1.00%)
What You Need to Know Ahead of Medtronic's Earnings Release

Medtronic is expected to release its fiscal fourth-quarter earnings soon, and analysts project a single-digit profit drop.

XLV : 146.63 (-0.05%)
$SPX : 7,501.24 (+0.77%)
MDT : 76.97 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience...

See More

Key Turning Points

3rd Resistance Point 78.57
2nd Resistance Point 77.84
1st Resistance Point 77.40
Last Price 76.97
1st Support Level 76.23
2nd Support Level 75.50
3rd Support Level 75.06

See More

52-Week High 106.33
Fibonacci 61.8% 94.13
Fibonacci 50% 90.37
Fibonacci 38.2% 86.60
Last Price 76.97
52-Week Low 74.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.